Gold prices bounce off 3-week lows; demand likely longer term
Walter S. Woltosz, a director and significant shareholder of Simulations Plus , Inc. (NASDAQ:SLP), has recently sold 20,000 shares of the company’s common stock. The shares were sold at prices ranging from $28.32 to $29.10, with an average price of $28.68, totaling approximately $573,600. The transaction comes as the stock has declined 31.58% over the past year, with the company currently trading at a P/E ratio of 70.8x.
Following this transaction, Woltosz holds 3,383,371 shares of Simulations Plus. The sale was executed under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks. This filing provides transparency for investors and adheres to SEC regulations. The company maintains strong financials with a current ratio of 4.15x and operates with minimal debt.
Simulations Plus, a provider of software for pharmaceutical research, continues to be a key player in the industry, with transactions like these offering insights into the activities of its major stakeholders. The company, valued at $580.47 million, has demonstrated solid growth with revenue increasing 19.84% over the last twelve months. InvestingPro analysis reveals 12 additional key insights about SLP’s financial health and growth prospects.
In other recent news, Simulations Plus has reported significant developments that may interest investors. The company recently announced its fourth-quarter earnings for fiscal year 2024, surpassing Wall Street expectations with an earnings per share (EPS) of $0.17, beating the forecast of $0.14. Simulations Plus also reported revenues of $18.9 million for the first quarter of fiscal year 2025, aligning closely with analyst projections. Additionally, the company has set its revenue guidance for fiscal year 2025 between $90 million and $93 million, including an expected contribution from the Proficiency acquisition.
In a related development, KeyBanc Capital Markets raised its price target for Simulations Plus shares from $35.00 to $37.00, maintaining an Overweight rating. Analysts from Oppenheimer also affirmed an Outperform rating on the stock, with a price target of $65.00, following the company’s positive first-quarter revenue report. During its Annual Meeting of Shareholders, Simulations Plus saw approximately 74% of its issued shares represented, electing five board members and ratifying Rose, Snyder & Jacobs LLP as its independent auditor for the fiscal year ending August 31, 2025.
The company continues to exhibit strong financial health, maintaining a debt-free position and holding $20 million in cash. KeyBanc highlighted the potential positive impact of the White House’s $500 billion Stargate Project initiative on the company’s valuation and growth prospects. These developments reflect a cautiously optimistic outlook for Simulations Plus, with analysts noting the company’s strategic positioning and potential for revenue growth in the upcoming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.